Wall Street analysts forecast that AzurRx BioPharma Inc (NASDAQ:AZRX) will report earnings of ($0.24) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for AzurRx BioPharma’s earnings. AzurRx BioPharma posted earnings of ($0.27) per share in the same quarter last year, which would suggest a positive year over year growth rate of 11.1%. The firm is scheduled to issue its next earnings report on Monday, September 17th.
According to Zacks, analysts expect that AzurRx BioPharma will report full year earnings of ($0.90) per share for the current year, with EPS estimates ranging from ($0.91) to ($0.88). For the next financial year, analysts expect that the firm will post earnings of ($0.76) per share, with EPS estimates ranging from ($0.78) to ($0.74). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for AzurRx BioPharma.
Separately, HC Wainwright set a $6.00 price target on AzurRx BioPharma and gave the company a “buy” rating in a report on Friday, May 25th.
AZRX traded up $0.01 on Wednesday, reaching $2.77. The company’s stock had a trading volume of 9,300 shares, compared to its average volume of 47,381. AzurRx BioPharma has a fifty-two week low of $2.20 and a fifty-two week high of $5.25.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Gilder Gagnon Howe & Co. LLC acquired a new position in AzurRx BioPharma in the second quarter valued at approximately $1,782,000. Parsons Capital Management Inc. RI boosted its holdings in AzurRx BioPharma by 20.3% in the first quarter. Parsons Capital Management Inc. RI now owns 329,515 shares of the company’s stock valued at $1,035,000 after purchasing an additional 55,540 shares in the last quarter. Ardsley Advisory Partners boosted its holdings in AzurRx BioPharma by 66.3% in the second quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock valued at $440,000 after purchasing an additional 54,697 shares in the last quarter. Finally, Opaleye Management Inc. acquired a new position in AzurRx BioPharma in the second quarter valued at approximately $417,000. 18.61% of the stock is owned by hedge funds and other institutional investors.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Read More: How Do You Calculate Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.